Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
RGC
Upturn stock ratingUpturn stock rating

Regencell Bioscience Holdings Ltd (RGC)

Upturn stock ratingUpturn stock rating
$3.8
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

01/29/2025: RGC (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -54.19%
Avg. Invested days 30
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 01/29/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 48.80M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 24691
Beta -0.59
52 Weeks Range 3.03 - 19.10
Updated Date 02/18/2025
52 Weeks Range 3.03 - 19.10
Updated Date 02/18/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.33

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -28.11%
Return on Equity (TTM) -43.18%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 40922753
Price to Sales(TTM) -
Enterprise Value 40922753
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -44.58
Shares Outstanding 13012900
Shares Floating 1439874
Shares Outstanding 13012900
Shares Floating 1439874
Percent Insiders 88.82
Percent Institutions 0.29

AI Summary

Regencell Bioscience Holdings Ltd. (RGC) Stock Analysis

Note: This analysis covers publicly available information as of November 6th, 2023. Recent developments may not be reflected in this report.

Company Profile

Background: Regencell Bioscience Holdings Ltd. (RGC) is a Cayman Island-based biopharmaceutical company focusing on the discovery, development, and commercialization of Traditional Chinese Medicine (TCM)-based treatments. Founded in 2010, RGC has subsidiaries in Hong Kong, China, and the United States.

Core Businesses: RGC's primary focus is on developing treatments for diseases related to degeneration and inflammation, utilizing both TCM and modern pharmaceuticals. Currently, the company's main research areas are:

  • Cell Therapy: RGC uses proprietary umbilical cord-derived mesenchymal stem cell (UC-MSC) technology for regenerative therapies.
  • TCM-based Therapeutics: RGC develops modernized and standardized versions of TCM treatments for conditions like osteoarthritis, diabetic foot ulcers, and other inflammatory diseases.

Leadership: The company's leadership includes:

  • CEO: Huan Liu
  • CFO: Yu Wang
  • CTO: Dawei Cui
  • President and Chief Scientific Officer: Daniel Teitelbaum

Top Products and Market Share

Top Products: RGC's flagship products include:

  • RGC-002: An allogeneic UC-MSC product for osteoarthritis treatment. RGC-002 received IND clearance from the US FDA and is in Phase I/II clinical trials.
  • RGC-004: A novel TCM formula for diabetic foot ulcers, currently in clinical trials in China.
  • RGC-008: An UC-MSC-based product for intervertebral disc degeneration, in the pre-clinical research stage.

Market Share: Estimating RGC's precise market share is challenging due to the company's early stage of development and the nascent nature of many of its targeted markets. However, the global cell therapy market is projected to reach $23.3 billion by 2025, and the global TCM market is expected to reach $324 billion by 2027, highlighting significant growth potential for RGC's products.

Competition: RGC faces competition from various companies developing cell therapies and TCM-based treatments. Key competitors include:

  • Athersys (ATHX): Developing multipotent adult progenitor cells (MAPCs) for various medical conditions.
  • Stemcells, Inc. (STEM): Offers various stem cell-based therapies through its clinics.
  • Sihuan Pharmaceutical Holdings Group Ltd. (SHPG): Develops and manufactures TCM and Western medicines in China.

Product Performance: RGC's RGC-002 demonstrated positive results in early-stage trials for osteoarthritis, showing improvements in pain and function. The ongoing late-stage trials will be crucial in determining its market viability.

Total Addressable Market

RGC's total addressable market (TAM) encompasses several segments:

  • Osteoarthritis Treatment: This global market is estimated to reach $30 billion by 2027, with significant unmet needs for new and effective therapies.
  • Diabetic Foot Ulcers: This global market is projected to reach $3.3 billion by 2027, representing a substantial opportunity for RGC's RGC-004 product.
  • Other Inflammatory Diseases: The global market for inflammatory disease treatments is vast and expected to grow steadily, offering significant opportunities for RGC's future pipeline of TCM-based therapeutics.

Financial Performance

As a relatively young company, RGC has yet to achieve profitability. Its recent financial performance reflects its ongoing research and development investments:

  • Revenue: Primarily from clinical trial services and limited product sales, RGC's revenue was $3.8 million in 2022.
  • Net Income: The company reported a net loss of $34 million in 2022 due to research and development expenses.
  • Profit Margins: Negative due to pre-commercial stage.
  • Earnings per Share (EPS): Negative EPS of $0.84 in 2022, reflecting losses.

Financial Performance Comparison: RGC's year-over-year revenue growth has been modest, with a 13.8% increase in 2022. However, its cash flow remains significantly negative due to ongoing R&D investments. The company is currently funded by a combination of grants, investments, and debt financing.

Dividends and Shareholder Returns

Dividend History: RGC has not yet initiated any dividend payments, focusing resources on growth and R&D.

Shareholder Returns: Since its IPO in 2021, RGC has experienced significant stock price volatility, with a total return of -42% as of November 6th, 2023. This volatility reflects the company's early stage of development and dependence on successful product development.

Growth Trajectory

Historical Growth: RGC has demonstrated steady growth in its research pipeline and early-stage clinical trials. The company has expanded its product portfolio and entered into strategic partnerships with research institutions.

Future Growth Projections: RGC's future growth heavily depends on the successful development and commercialization of its lead product candidates, RGC-002 and RGC-004. Success in these endeavors could unlock significant market opportunities and drive future revenue growth.

Recent Strategic Initiatives: RGC has been actively pursuing various initiatives to support its growth plans:

  • Clinical Trial Expansion: Initiating Phase I/II trials for RGC-002 in the United States and expanding trials for RGC-004 in China.
  • Collaboration: Partnering with research institutions to further develop its UC-MSC platform and TCM-based therapeutics.
  • Market Expansion: Pursuing regulatory approvals for its products in various international markets.

Market Dynamics

Industry Trends: The cell therapy and TCM markets are experiencing continued growth, driven by rising healthcare spending, an aging population, and increasing demand for innovative treatment options. Technological advancements and regulatory changes are also shaping the landscape, creating both opportunities and challenges for companies like RGC.

Positioning: RGC's focus on both cell therapy and TCM positions the company to capitalize on the strengths of each approach. Its UC-MSC platform offers the potential for regenerative treatments, while its TCM-based approach leverages traditional knowledge and potentially reduces side effects associated with Western medicine. Adaptability to changing market dynamics will be critical for RGC's success.

Potential Challenges and Opportunities

Key Challenges: RGC faces several challenges:

  • Clinical Trial Success: The successful completion of clinical trials for RGC's lead products is crucial for regulatory approval and market entry.
  • Competition: The company operates in highly competitive markets, requiring differentiation and a strong value proposition to succeed.
  • Regulatory Environment: Navigating complex regulatory processes for cell therapy and TCM products presents ongoing challenges.

Potential Opportunities: RGC also has significant opportunities:

  • Large Market Potential: Addressing unmet needs in sizeable global markets for conditions like osteoarthritis and diabetic foot ulcers offers substantial growth potential.
  • Innovation: Combining cell therapy with TCM offers a unique value proposition and potential for differentiation in the market.
  • Strategic Partnerships: Collaboration with research institutions and industry players can accelerate development and expand market reach.

Recent Acquisitions (last 3 years)

RGC has not completed any acquisitions in the last three years, focusing on internal research and development activities.

AI-Based Fundamental Rating

Rating: Based on available data, RGC's AI-based fundamental rating is 5 out of 10.

Justification: This rating reflects the company's promising pipeline, significant addressable market, and innovative approach. However, the early stage of development, lack of profitability, and competitive landscape warrant caution. The success of RGC's ongoing clinical trials and its ability to navigate a dynamic market will be crucial factors determining its future success.

Sources and Disclaimers

This analysis was compiled using information from the following sources:

  • Regencell Bioscience Holdings Ltd. website (https://www.regencellbio.com/)
  • Securities and Exchange Commission (SEC) filings
  • Investor relations presentations
  • Market research reports from reputable firms

This information should not be considered financial advice. Investment decisions should be made with the help of a qualified financial advisor and based on individual circumstances and risk tolerance.

Conclusion

Regencell Bioscience Holdings Ltd. presents a compelling case study of a company pursuing innovative solutions for treating inflammatory and degenerative diseases. Despite the early stage of development and inherent risks associated with emerging biopharmaceutical companies, RGC has the potential to unlock significant value if it successfully commercializes its promising pipeline. Continued monitoring of clinical trial进展, regulatory developments, and the company's strategic initiatives will be crucial for assessing its future prospects.

About Regencell Bioscience Holdings Ltd

Exchange NASDAQ
Headquaters -
IPO Launch date 2021-07-16
Founder, Chairman & CEO Mr. Yat-Gai Au
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 12
Full time employees 12

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. The company focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. Regencell Bioscience Holdings Limited was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​